珍寶島(603567.SH):穿心蓮內酯改構化合物獲得美國專利授權
格隆匯9月24日丨珍寶島(603567.SH)公佈,近日,公司收到美國專利局頒發的《專利授權證書》。發明名稱為“穿心蓮內酯改構化合物”,專利號為“US 10,717,720 B2”,專利權期限為自申請之日起20年。
穿心蓮內酯因具有清熱解毒、抗菌消炎等藥理作用在臨牀上被廣泛應用,具有較好的研發價值,其改構化合物的作用研究主要是針對肺纖維化。公司ZBD0276項目即是在穿心蓮內酯基礎上,通過化學改構研發獲得。
以上《專利授權證書》的獲得是穿心蓮內酯改構化合物首次在國際方面獲得的專利,也是公司獲得的第三個美國專利;是公司在專利保護方面邁向國際的又一大進步,也是公司在創新藥品研究方面的重大進展,有利於進一步完善公司知識產權保護體系,充分發揮自主知識產權的技術優勢,促進技術創新,從而提升公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.